B3GNT2

Across TCGA pan-cancer cohorts, B3GNT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B3GNT2 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher B3GNT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated B3GNT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where B3GNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.329	0.979	.006	16	view →
LSCC	DFS	Median	II,III,IV	0.839	1.000	.006	11	view →
HNSC	OS	Tertile	All	0.618	0.872	.010	5	view →
UCEC	OS	Median	All	0.975	0.841	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B3GNT2–PDAC (DFS)

Open the PDAC breakdown →